First-line treatment options for patients with HER-2-negative metastatic breast cancer: The impact of modern adjuvant chemotherapy

Oncologist

Volumn 12, Issue 7, 2007, Pages 785-797

  Verma, Sunil ^a,c   Clemons, Mark ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant; Anthracycline; Capecitabine; First line; Metastatic breast cancer; Taxane

Indexed keywords

ALBUMIN; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; METHOTREXATE; MITOMYCIN C; NANOPARTICLE; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME;

EID: 34548269064     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-7-785     Document Type: Review

References (76)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2003. Available at http://seer.cancer.gov/csr/1975_2003/results_merged/sect_04_breast. pdf. Accessed July 4, 2006.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23:3686-3696.
4. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
5. Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004;88:S16.
6. US Tandem breast cancer supplemental study MAT Q1 2006.
7. Tendler View Oncology. Xeloda: Use in 1st line BC metastatic setting: March 2006 Wave. April 2006.
8. Synovate European Cancer Monitor MAT Q1 2006. F. Hoffmann-La Roche, data on file 2006.
9. Colozza M, de Azambuja E, Cardoso F et al. Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era. The Oncologist 2006;11:111-125.
10. Campone M, Fumoleau P, Bourbouloux E et al. Taxanes in adjuvant breast cancer setting: Which standard in Europe? Crit Rev Oncol Hematol 2005;55:167-175.
11. Fumoleau P, Bonneterre J, Luporsi E. Adjuvant chemotherapy for nodepositive breast cancer patients: Which is the reference today? J Clin Oncol 2003;21:1190-1191; author reply 1191-1192.
12. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
13. Poole CJ, Earl HM, Hiller L et al.; NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851-1862.
14. Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-225.
15. Pacilio C, Morabito A, Nuzzo F et al. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicincontaining adjuvant treatment? A single centre phase III trial. Br J Cancer 2006;94:1233-1236.
16. Al-Batran SE, Bischoff J, von Minckwitz G et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: A multicentre phase II trial. Br J Cancer 2006;94:1615-1620.
17. Rivera E, Valero V, Esteva FJ et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002;49:299-302.
18. Fabi A, Ferretti G, Papaldo P et al. Pegylated liposomal doxorubicin in combination with gemcitabine: A phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol 2006;57:615-623.
19. Rivera E, Valero V, Arun B et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3249-3254.
20. Ardavanis A, Mavroudis D, Kalbakis K et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: A multicentre phase II study. Cancer Chemother Pharmacol 2006;58:742-748.
21. Trudeau ME, Provencher L, Panasci L. Pegylated liposomal doxorubicin (PLD) plus cyclophosphamide as 1st-line therapy for metastatic breast cancer in patients previously treated with anthracyclines. J Clin Oncol 2005;23(suppl 16):745.
22. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-5551.
23. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-2823.
24. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-1215.
25. Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004;22(suppl 14):510.
26. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
27. Beslija S, Obralic N, Basic H et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2006;24(suppl 18):571.
28. Soto C, Torrecillas L, Reyes S et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006;24(suppl 18):570.
29. Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. J Clin Oncol 2005;23(suppl 16):581.
30. Khoo K-S, Zaidi M, Srimuninnimit V et al. Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). J Clin Oncol 2004;22(suppl 14):710.
31. Langley RE, Carmichael J, Jones AL et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute Trial AB01. J Clin Oncol 2005;23:8322-8330.
32. Fountzilas G, Kalofonos HP, Dafni U et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15:1517-1526.
33. Fountzilas G, Papadimitriou C, Dafni U et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 2001;19:2232-2239.
34. Mavroudis D, Boukovinas I, Ardavanis A et al. A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report. Presented at the 2005 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2005.
35. O'Brien MER, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil® versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
36. Batist G, Harris L, Azarnia N et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anticancer Drugs 2006;17:587-595.
37. Venturini M, Bruzzi P, Del Mastro L et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996;14:764-773.
38. Gennari A, Bruzzi P, Orlandini C et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 2004;90:962-967.
39. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006;17:1379-1385.
40. Joensuu H, Hemminki A, Huovinen R et al. The FinXX trial: Safety results in 600 patients (pts) randomized to either docetaxel (T) followed by cyclophosphamide (C) + epirubicin (E) + 5-FU (F) (CEF) or T + capecitabine (X) followed by CEX as adjuvant therapy for early breast cancer (BC). J Clin Oncol 2007;25(suppl 18):11035.
41. Fumoleau P, Romieu G, Chan S et al. Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. J Clin Oncol 2006;24(suppl 18):682.
42. th April 2007). In: electronic Medicines Compendium (eMC). Available at http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 15748#CLINICAL_PARTS. Accessed April 17, 2007.
43. Finek J, Holubec L, Elgrova L et al. The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer. J Clin Oncol 2006;24(suppl 18):10605.
44. Marti JL, Bueso P, Mayordomo JI et al. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Ann Oncol 2001;12:1061-1065.
45. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-1884.
46. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-4223.
47. Taguchi T, Aihara T, Takatsuka Y et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 2004;10:509-513.
48. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
49. O'Shaughnessy JA, Blum JL, Sandbach JF et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Presented at the 2005 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2005.
50. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
51. Keller AM, Mennel RG, Georgoulias VA et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893-3901.
52. Mavroudis D, Ardavanis A, Boukovinas I et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report. J Clin Oncol 2006;24(suppl 18):658.
53. Perez EA, Hillman DW, Mailliard JA et al. Randomized phase II study or two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004;22:2849-2855.
54. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
55. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
56. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
57. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
58. Largillier R, Fumoleau P, Clippe C et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): Long-term survival data. Ann Oncol 2006;17(suppl 9):ix74.
59. Fazeny B, Zifko U, Meryn S et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996;39:150-156.
60. Smorenburg C, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer (MBC) relapsing or failing on both an anthracycline (A) and a taxane (T). Ann Oncol 2000;11:31.
61. Udom DI, Vigushin DM, Linardou H et al. Two weekly vinorelbine: Administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36:177-182.
62. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-2272.
63. Jara-Sánchez C, Martin M, García-Sáenz JA et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A cooperative study by the GEICAM group. Clin Breast Cancer 2003;3:399-404.
64. Ibrahim NK, Valero V, Rahman Z et al. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: Cumulative toxicities limit dose escalation. Cancer Invest 2001;19:459-466.
65. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-1400.
66. Pivot X, Thomas E, Lerzo G et al. Ixabepilone in patients (pts) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine. Ann Oncol 2006;17(suppl 9):ix70.
67. Conte P, Thomas E, Martin M et al. Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report. J Clin Oncol 2006;24(suppl 18):10505.
68. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-2734.
69. Denduluri N, Lee JJ, Walshe J et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25:63-67.
70. Martin M, Spielmann M, Namer M et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14:1246-1252.
71. O'Shaughnessy JA, Clark RS, Blum JL et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6:143-149.
72. Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986;58:1411-1417.
73. Castiglione-Gertsch M, Tattersall M, Hacking A et al. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 1997;33:2321-2325.
74. Bria E, Giannarelli D, Felici A et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 2005;103:672-679.
75. Lück H-J, von Minckwitz G, Du Bois A et al. Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 2006;24(suppl 18):517.
76. Stockler MR, Sourjina T, Harvey V et al. A randomised trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast caner unsuited to more intensive treatment. Breast Cancer Res Treat 2006;100(suppl 1):S278.